News

Canon Medical Systems USA Inc. Announces Expansion of Distributorship with the Acquisition of NXC Imaging

Tustin, California, (GLOBE NEWSWIRE) — Canon Medical Systems USA Inc., a commercial subsidiary of Canon Medical Systems Corporation and a global leader in innovative diagnostic imaging technology, today announces it has signed a definitive agreement to acquire NXC Imaging, a medical imaging equipment distributor and service provider headquartered in Minneapolis, Minnesota. Founded in 1964, NXC Imaging’s distributorship area spans the U.S. Upper Midwest. The acquisition is expected to close in the third quarter of the 2022 calendar year.

The addition of NXC Imaging to Canon Medical Systems USA will strengthen its sales and service channels across the Upper Midwest in Canon’s diagnostic imaging portfolio that includes modalities of Computed Tomography (CT), Positron Emission Tomography (PET), Magnetic Resonance (MR), X-ray (XR), Vascular Imaging (VL) and Ultrasound (UL). Canon Medical plans to continue building its substantial sales and service organization, offering innovative solutions and unique business models tailored to each client’s specific needs.

“We have partnered with NXC Imaging for over 33 years,” said Yuji Hamada, CEO and President of Canon Medical Systems USA Inc. “Our successful partnership has thrived due to Canon’s innovative technology and trusting collaboration with NXC’s entrepreneurial company culture. The results of our partnership have demonstrated strong results over the past 15 years in the Upper Midwest region.”

“Our company’s foundation was built on our long-term customer relationships, trust, and loyalty in our territories. As a result, we have provided exceptional technology solutions and best-in-class support. We are proud of the legacy we’ve created and know that as a part of Canon Medical, we will continue to provide the Upper Midwest region with the same “Never Ordinary” customer service we are known for,” stated Bruce Zeilinger, President, and CEO of NXC Imaging.

Read more here.

Recent News

04/23/2024

AMPEL BioSolutions Selected as Member of Prestigious Federal Health Innovation ARPA-H Network

AMPEL BioSolutions has been selected as a member – or “spoke” – of the Customer Experience Hub of ARPANET-H, a prestigious nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).  This national effort is designed to accelerate commercialization of health breakthroughs for populations that urgently need them. The Customer Experience Hub in Dallas joins Boston

04/19/2024

ivWatch prevents IV leakage events at Frimley Health

Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous

04/17/2024

U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure

Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to develop the latest generation pralidoxime chloride auto-injector as a countermeasure against organophosphate or nerve agent poisoning.